Semigran Marc - 24 Jan 2022 Form 4 Insider Report for Renovacor, Inc.

Reporting relationship: Chief Medical Officer
Issuer ticker: N/A
Reported as of: 24 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jan 2022, 17:30:32 UTC
Prior SEC filing: 22 Dec 2021
Next SEC filing: 05 Dec 2022
Source filing: View source filing
Reporting owner signature: /s/ Joseph Carroll, as attorney-in-fact

Key filing fact

Semigran Marc filed Form 4 for Renovacor, Inc. on 26 Jan 2022.

Key facts

This page summarizes Semigran Marc's Form 4 filing for Renovacor, Inc..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 26 Jan 2022, 17:30.

Change

Previous filing in this sequence was filed on 22 Dec 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCOR transaction

Common Stock

Award

Transaction value: $0
Shares: +17,425
Change %: +49%
Price: $0.000000
Shares after: 52,651
Date: 24 Jan 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RCOR transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +34,850
Change %
Price: $0.000000
Shares after: 34,850
Date: 24 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,850
Exercise price: $6.45
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These restricted stock units will vest in four equal annual installments beginning on January 24, 2023, subject to continued service with the Company.

Footnote F2

The stock option will vest and become exercisable in full on January 24, 2026, with 25% vesting on January 24, 2023, and the remainder vesting in equal monthly installments on the24th of each month for the remaining 36months, subject to the continuous service of the Reporting Person on such vesting date.